Arcturus Therapeutics Holdings Inc (ARCT)

Sep 25, 2026

Arcturus Therapeutics announced encouraging preliminary Phase II data for its ARCT-810 program for OTC deficiency, showing normal ammonia levels and reduced glutamine in participants with mild to moderate adverse events. The company also introduced LUNAR 2.0, a new delivery platform offering significantly higher protein expression, which will be incorporated into ARCT-2601 for potential lower doses and shorter infusions. Arcturus plans a Phase II/III pediatric trial in late 2027 and is expanding its preclinical mRNA programs for PKU and gout, alongside acquiring computational immunology company myNEO.

Sep 24, 2026

Citi has upgraded Arcturus Therapeutics (ARCT) stock to Buy from Neutral following positive mid-stage trial data for its experimental liver disease drug, ARCT-810. Analyst Yigal Nochomovitz cited the promising results for the messenger RNA therapy designed to treat ornithine transcarbamylase deficiency.

Sep 24, 2026

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) has announced the presentation of Phase 2 clinical trial data for its ARCT-810 candidate and provided an update on its mRNA delivery platform. This information was disclosed via a Form 8-K filing on September 23, 2026, which included a presentation and a press release summarizing the data. The filing ensures compliance with Regulation FD, mandating broad disclosure of material nonpublic information.